Mesenchymal stem cell-derived cell-free technologies: a patent landscape.
Biotechnol Lett
; 46(5): 907-924, 2024 Oct.
Article
en En
| MEDLINE
| ID: mdl-38900338
ABSTRACT
Mesenchymal stem/stromal cells (MSC) play a pivotal role in regenerative therapies. Recent studies show that factors secreted by MSC can replicate their biological activity, driving the emergence of cell-free therapy, likely to surpass stem cell therapy. Patents are an objective measure of R&D and innovation activities, and patent mapping allows us to verify the state of the art and technology, anticipate trends, and identify emerging lines of research. This review performed a search on Derwent World Patents Index™ and retrieved 269 patent families related to the MSC-derived cell-free products. Analysis reveals an exponential increase in patents from the mid-2010s, primarily focusing on exosomes. The patent's contents offer a great diversity of applications and associated technologies by using the products as medicinal agents or drug delivery systems. Nevertheless, numerous application branches remain unexplored, suggesting vast potential for cell-free technologies alone or combined with other approaches.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Patentes como Asunto
/
Células Madre Mesenquimatosas
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Biotechnol Lett
/
Biotechnol. lett
/
Biotechnology letters
Año:
2024
Tipo del documento:
Article
País de afiliación:
Brasil
Pais de publicación:
Países Bajos